Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Transplantation and Cellular Therapy
|
October 22, 2022
A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy
Jack Badaracco, Matthew Gitlin, Scott J Keating
Future Oncology (London, England)
|
January 17, 2024
Treatment patterns and costs among US patients with diffuse large B-cell lymphoma not treated with 2L stem cell transplantation
Teofilia Acheampong, Tao Gu, Trong Kim Le, et al.
Transplantation and Cellular Therapy
|
March 30, 2022
Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States
Scott J Keating, Tao Gu, Monika P Jun, et al.
Transplantation and Cellular Therapy
|
August 6, 2023
Estimating the Cost per Clinical Outcome of Second-Line Liso-Cel Versus Autologous Stem Cell Transplantation in Patients with Transplantation-Intended Relapsed/Refractory Large B Cell Lymphoma
Matia Saeedian, Jack Badaracco, Afraim Botros, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 22, 2023
Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia
Andrew J Klink, Scott J Keating, John Brokars, et al.
Regional Anesthesia and Pain Medicine
|
June 26, 2026
New persistent opioid use following surgery among opioid-naïve patients in the USA: a systematic review and meta-analysis of observational studies
Stephan Frangakis, Scott J Keating, Konrad Pisarczyk, et al.
Advances in Therapy
|
March 22, 2023
Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
Christopher Parker, Fei Fei Liu, Kristen A Deger, et al.
Leukemia & Lymphoma
|
May 21, 2021
Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials
M Lia Palomba, Monika Parisi Jun, James Lymp, et al.
Pain and Therapy
|
May 15, 2026
Surgeon Perceptions and Experiences with Postoperative Acute Pain Management: A Mixed-Methods Study
Vinod Dasa, Scott J Keating, Sushanth Jeyakumar, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Transplantation and Cellular Therapy
|
October 22, 2022
A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy
Jack Badaracco, Matthew Gitlin, Scott J Keating
Future Oncology (London, England)
|
January 17, 2024
Treatment patterns and costs among US patients with diffuse large B-cell lymphoma not treated with 2L stem cell transplantation
Teofilia Acheampong, Tao Gu, Trong Kim Le, et al.
Transplantation and Cellular Therapy
|
March 30, 2022
Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States
Scott J Keating, Tao Gu, Monika P Jun, et al.
Transplantation and Cellular Therapy
|
August 6, 2023
Estimating the Cost per Clinical Outcome of Second-Line Liso-Cel Versus Autologous Stem Cell Transplantation in Patients with Transplantation-Intended Relapsed/Refractory Large B Cell Lymphoma
Matia Saeedian, Jack Badaracco, Afraim Botros, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 22, 2023
Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia
Andrew J Klink, Scott J Keating, John Brokars, et al.
Regional Anesthesia and Pain Medicine
|
June 26, 2026
New persistent opioid use following surgery among opioid-naïve patients in the USA: a systematic review and meta-analysis of observational studies
Stephan Frangakis, Scott J Keating, Konrad Pisarczyk, et al.
Advances in Therapy
|
March 22, 2023
Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
Christopher Parker, Fei Fei Liu, Kristen A Deger, et al.
Leukemia & Lymphoma
|
May 21, 2021
Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials
M Lia Palomba, Monika Parisi Jun, James Lymp, et al.
Pain and Therapy
|
May 15, 2026
Surgeon Perceptions and Experiences with Postoperative Acute Pain Management: A Mixed-Methods Study
Vinod Dasa, Scott J Keating, Sushanth Jeyakumar, et al.
Page
of 1